Industry Briefs: November 19, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 19, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Allergan has agreed to acquire SkinMedica’s topical aesthetics skin-care business. Read More

bioMérieux and Quanterix have entered into an agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial applications. Read More

GVK Biosciences has received approvals from the Atomic Energy Regulatory Board and the Indian government, to carry out 3H and 14C synthesis activities. Read More

Jubilant HollisterStier has announced that its contract manufacturing and services division has secured more than $100 million in contracts with leading pharmaceutical companies for the commercial manufacturing of multiple sterile parenteral products. Read More

Pacific BioLabs has acquired Bay Bioanalytical Laboratory, thus adding analytical and bioanalytical chemistry to Pacific BioLabs’ existing in vivo preclinical and microbiological testing services. Read More

Recipharm and Vetcare have entered into an agreement for the development and manufacture of a parenteral veterinary product. Read More

Sensient Pharmaceutical has extended its proprietary line of Microfine natural colors to provide a complete natural color coating system ideal for the nutraceutical market. Read More

Synerlab and AXA Private Equity have announced the acquisitions of Lyofal and IDD-TECH Orleans. Read More

People News

Onyx Scientific has appointed Dan Brisard business development director. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
43%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
14%
Raw material supply problems
14%
Regulatory restrictions
0%
Business decisions to limit production
29%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced

Click here